Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C
Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups t...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 753.e3 |
|---|---|
| container_issue | 3 |
| container_start_page | 744 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 146 |
| creator | Buti, Maria Agarwal, Kosh Horsmans, Yves Sievert, William Janczewska, Ewa Zeuzem, Stefan Nyberg, Lisa Brown, Robert S Hézode, Christophe Rizzetto, Mario Paraná, Raymundo De Meyer, Sandra De Masi, Ralph Luo, Donghan Bertelsen, Kirk Witek, James |
| description | Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level of HCV RNA at week 4 was |
| doi_str_mv | 10.1053/j.gastro.2013.11.047 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1501834350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0016508513017289</els_id><sourcerecordid>1501834350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-94dc4bd5158a00c7b9b02ee0fd1b2d4a71febb5367126dec09b5d2506f7489693</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6D0Ry9NJtVdLpj4sgs6uzsKjgiMeQTlfvZuzpjElmZP69GWYV8eKpIHneKuopxl4ilAhKvtmUdyam4EsBKEvEEqrmEVugEm0BgOIxW-RSFwpadcGexbgBgE62-JRdiEpiLWqxYHdrmswu0MEFvv7pLPEr46Yjv4n8o5_dPFJwPvDk-V_g9YHCkbd85fch8jH_fzbJ0Zwi_-bSPV_eh5y1fEW7_J5c5Mvn7MlopkgvHuol-_r-er1cFbefPtws390WtqplKrpqsFU_KFStAbBN3_UgiGAcsBdDZRocqe-VrBsU9UAWul4NQkE9NlXb1Z28ZK_PfXfB_9hTTHrroqVpMjP5fdSoAFtZSQUZrc6oDT7GQKPeBbc14agR9Emx3uizYn1SrBF1Vpxjrx4m7PstDX9Cv51m4O0ZoLznwVHQ0WY5lgYXyCY9ePe_Cf82sJPLPs30nY4UN9n6nB1q1FFo0F9OZz5dGSVgI9pO_gKrS6OV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1501834350</pqid></control><display><type>article</type><title>Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C</title><source>MEDLINE</source><source>ScienceDirect Freedom Collection (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Buti, Maria ; Agarwal, Kosh ; Horsmans, Yves ; Sievert, William ; Janczewska, Ewa ; Zeuzem, Stefan ; Nyberg, Lisa ; Brown, Robert S ; Hézode, Christophe ; Rizzetto, Mario ; Paraná, Raymundo ; De Meyer, Sandra ; De Masi, Ralph ; Luo, Donghan ; Bertelsen, Kirk ; Witek, James</creator><creatorcontrib>Buti, Maria ; Agarwal, Kosh ; Horsmans, Yves ; Sievert, William ; Janczewska, Ewa ; Zeuzem, Stefan ; Nyberg, Lisa ; Brown, Robert S ; Hézode, Christophe ; Rizzetto, Mario ; Paraná, Raymundo ; De Meyer, Sandra ; De Masi, Ralph ; Luo, Donghan ; Bertelsen, Kirk ; Witek, James</creatorcontrib><description>Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level of HCV RNA at week 4 was <25 IU/mL or for 36 weeks if their level was higher. The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every 8 hours in producing a sustained virological response 12 weeks after the end of therapy (SVR12) (based on a –11% lower limit of the 95% lower confidence interval for the difference between groups). Results At baseline, of 740 patients, 85% had levels of HCV RNA ≥800,000 IU/mL, 28% had fibrosis (F3–F4), 14% had cirrhosis (F4), 57% were infected with HCV genotype 1a, and 71% had the non-CC IL28B genotype. Of patients who were treated with telaprevir twice daily, 74.3% achieved SVR12 compared with 72.8% of patients who were treated with telaprevir every 8 hours (difference in response, 1.5%; 95% confidence interval, –4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours. All subgroups of patients who were treated with telaprevir twice daily versus those who were treated every 8 hours had similar rates of SVR12. The most frequent adverse events (AEs) in the telaprevir phase were fatigue (47%), pruritus (43%), anemia (42%), nausea (37%), rash (35%), and headache (26%); serious AEs were reported in 9% of patients. Rates of AEs and serious AEs were similar or slightly higher among patients treated with telaprevir every 8 hours. Conclusions Based on a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with similar levels of safety and tolerability. These results support use of telaprevir twice daily in patients with chronic HCV genotype 1 infection, including those with cirrhosis. ClinicalTrials.gov , Number: NCT01241760.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1053/j.gastro.2013.11.047</identifier><identifier>PMID: 24316262</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Clinical Trial ; DAA ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Therapy, Combination ; Fatigue - epidemiology ; Female ; Gastroenterology and Hepatology ; Genotype ; Headache - epidemiology ; Hepacivirus - genetics ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Humans ; Incidence ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Nausea - epidemiology ; Oligopeptides - administration & dosage ; Oligopeptides - adverse effects ; Oligopeptides - therapeutic use ; OPTIMIZE ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; Protease Inhibitor ; Recombinant Proteins - adverse effects ; Recombinant Proteins - therapeutic use ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; RNA, Viral - blood ; Treatment Outcome</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3</ispartof><rights>AGA Institute</rights><rights>2014 AGA Institute</rights><rights>Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-94dc4bd5158a00c7b9b02ee0fd1b2d4a71febb5367126dec09b5d2506f7489693</citedby><cites>FETCH-LOGICAL-c463t-94dc4bd5158a00c7b9b02ee0fd1b2d4a71febb5367126dec09b5d2506f7489693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.gastro.2013.11.047$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24316262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Buti, Maria</creatorcontrib><creatorcontrib>Agarwal, Kosh</creatorcontrib><creatorcontrib>Horsmans, Yves</creatorcontrib><creatorcontrib>Sievert, William</creatorcontrib><creatorcontrib>Janczewska, Ewa</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Nyberg, Lisa</creatorcontrib><creatorcontrib>Brown, Robert S</creatorcontrib><creatorcontrib>Hézode, Christophe</creatorcontrib><creatorcontrib>Rizzetto, Mario</creatorcontrib><creatorcontrib>Paraná, Raymundo</creatorcontrib><creatorcontrib>De Meyer, Sandra</creatorcontrib><creatorcontrib>De Masi, Ralph</creatorcontrib><creatorcontrib>Luo, Donghan</creatorcontrib><creatorcontrib>Bertelsen, Kirk</creatorcontrib><creatorcontrib>Witek, James</creatorcontrib><title>Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level of HCV RNA at week 4 was <25 IU/mL or for 36 weeks if their level was higher. The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every 8 hours in producing a sustained virological response 12 weeks after the end of therapy (SVR12) (based on a –11% lower limit of the 95% lower confidence interval for the difference between groups). Results At baseline, of 740 patients, 85% had levels of HCV RNA ≥800,000 IU/mL, 28% had fibrosis (F3–F4), 14% had cirrhosis (F4), 57% were infected with HCV genotype 1a, and 71% had the non-CC IL28B genotype. Of patients who were treated with telaprevir twice daily, 74.3% achieved SVR12 compared with 72.8% of patients who were treated with telaprevir every 8 hours (difference in response, 1.5%; 95% confidence interval, –4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours. All subgroups of patients who were treated with telaprevir twice daily versus those who were treated every 8 hours had similar rates of SVR12. The most frequent adverse events (AEs) in the telaprevir phase were fatigue (47%), pruritus (43%), anemia (42%), nausea (37%), rash (35%), and headache (26%); serious AEs were reported in 9% of patients. Rates of AEs and serious AEs were similar or slightly higher among patients treated with telaprevir every 8 hours. Conclusions Based on a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with similar levels of safety and tolerability. These results support use of telaprevir twice daily in patients with chronic HCV genotype 1 infection, including those with cirrhosis. ClinicalTrials.gov , Number: NCT01241760.</description><subject>Adult</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Clinical Trial</subject><subject>DAA</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Fatigue - epidemiology</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Genotype</subject><subject>Headache - epidemiology</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nausea - epidemiology</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - adverse effects</subject><subject>Oligopeptides - therapeutic use</subject><subject>OPTIMIZE</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Protease Inhibitor</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA, Viral - blood</subject><subject>Treatment Outcome</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6D0Ry9NJtVdLpj4sgs6uzsKjgiMeQTlfvZuzpjElmZP69GWYV8eKpIHneKuopxl4ilAhKvtmUdyam4EsBKEvEEqrmEVugEm0BgOIxW-RSFwpadcGexbgBgE62-JRdiEpiLWqxYHdrmswu0MEFvv7pLPEr46Yjv4n8o5_dPFJwPvDk-V_g9YHCkbd85fch8jH_fzbJ0Zwi_-bSPV_eh5y1fEW7_J5c5Mvn7MlopkgvHuol-_r-er1cFbefPtws390WtqplKrpqsFU_KFStAbBN3_UgiGAcsBdDZRocqe-VrBsU9UAWul4NQkE9NlXb1Z28ZK_PfXfB_9hTTHrroqVpMjP5fdSoAFtZSQUZrc6oDT7GQKPeBbc14agR9Emx3uizYn1SrBF1Vpxjrx4m7PstDX9Cv51m4O0ZoLznwVHQ0WY5lgYXyCY9ePe_Cf82sJPLPs30nY4UN9n6nB1q1FFo0F9OZz5dGSVgI9pO_gKrS6OV</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Buti, Maria</creator><creator>Agarwal, Kosh</creator><creator>Horsmans, Yves</creator><creator>Sievert, William</creator><creator>Janczewska, Ewa</creator><creator>Zeuzem, Stefan</creator><creator>Nyberg, Lisa</creator><creator>Brown, Robert S</creator><creator>Hézode, Christophe</creator><creator>Rizzetto, Mario</creator><creator>Paraná, Raymundo</creator><creator>De Meyer, Sandra</creator><creator>De Masi, Ralph</creator><creator>Luo, Donghan</creator><creator>Bertelsen, Kirk</creator><creator>Witek, James</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140301</creationdate><title>Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C</title><author>Buti, Maria ; Agarwal, Kosh ; Horsmans, Yves ; Sievert, William ; Janczewska, Ewa ; Zeuzem, Stefan ; Nyberg, Lisa ; Brown, Robert S ; Hézode, Christophe ; Rizzetto, Mario ; Paraná, Raymundo ; De Meyer, Sandra ; De Masi, Ralph ; Luo, Donghan ; Bertelsen, Kirk ; Witek, James</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-94dc4bd5158a00c7b9b02ee0fd1b2d4a71febb5367126dec09b5d2506f7489693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Clinical Trial</topic><topic>DAA</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Fatigue - epidemiology</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Genotype</topic><topic>Headache - epidemiology</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nausea - epidemiology</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - adverse effects</topic><topic>Oligopeptides - therapeutic use</topic><topic>OPTIMIZE</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Protease Inhibitor</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA, Viral - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buti, Maria</creatorcontrib><creatorcontrib>Agarwal, Kosh</creatorcontrib><creatorcontrib>Horsmans, Yves</creatorcontrib><creatorcontrib>Sievert, William</creatorcontrib><creatorcontrib>Janczewska, Ewa</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Nyberg, Lisa</creatorcontrib><creatorcontrib>Brown, Robert S</creatorcontrib><creatorcontrib>Hézode, Christophe</creatorcontrib><creatorcontrib>Rizzetto, Mario</creatorcontrib><creatorcontrib>Paraná, Raymundo</creatorcontrib><creatorcontrib>De Meyer, Sandra</creatorcontrib><creatorcontrib>De Masi, Ralph</creatorcontrib><creatorcontrib>Luo, Donghan</creatorcontrib><creatorcontrib>Bertelsen, Kirk</creatorcontrib><creatorcontrib>Witek, James</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buti, Maria</au><au>Agarwal, Kosh</au><au>Horsmans, Yves</au><au>Sievert, William</au><au>Janczewska, Ewa</au><au>Zeuzem, Stefan</au><au>Nyberg, Lisa</au><au>Brown, Robert S</au><au>Hézode, Christophe</au><au>Rizzetto, Mario</au><au>Paraná, Raymundo</au><au>De Meyer, Sandra</au><au>De Masi, Ralph</au><au>Luo, Donghan</au><au>Bertelsen, Kirk</au><au>Witek, James</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>146</volume><issue>3</issue><spage>744</spage><epage>753.e3</epage><pages>744-753.e3</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><abstract>Background & Aims We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Methods Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level of HCV RNA at week 4 was <25 IU/mL or for 36 weeks if their level was higher. The primary objective was to demonstrate noninferiority of telaprevir twice daily versus every 8 hours in producing a sustained virological response 12 weeks after the end of therapy (SVR12) (based on a –11% lower limit of the 95% lower confidence interval for the difference between groups). Results At baseline, of 740 patients, 85% had levels of HCV RNA ≥800,000 IU/mL, 28% had fibrosis (F3–F4), 14% had cirrhosis (F4), 57% were infected with HCV genotype 1a, and 71% had the non-CC IL28B genotype. Of patients who were treated with telaprevir twice daily, 74.3% achieved SVR12 compared with 72.8% of patients who were treated with telaprevir every 8 hours (difference in response, 1.5%; 95% confidence interval, –4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours. All subgroups of patients who were treated with telaprevir twice daily versus those who were treated every 8 hours had similar rates of SVR12. The most frequent adverse events (AEs) in the telaprevir phase were fatigue (47%), pruritus (43%), anemia (42%), nausea (37%), rash (35%), and headache (26%); serious AEs were reported in 9% of patients. Rates of AEs and serious AEs were similar or slightly higher among patients treated with telaprevir every 8 hours. Conclusions Based on a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with similar levels of safety and tolerability. These results support use of telaprevir twice daily in patients with chronic HCV genotype 1 infection, including those with cirrhosis. ClinicalTrials.gov , Number: NCT01241760.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24316262</pmid><doi>10.1053/j.gastro.2013.11.047</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1501834350 |
| source | MEDLINE; ScienceDirect Freedom Collection (Elsevier); Alma/SFX Local Collection |
| subjects | Adult Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Clinical Trial DAA Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Fatigue - epidemiology Female Gastroenterology and Hepatology Genotype Headache - epidemiology Hepacivirus - genetics Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Humans Incidence Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Male Middle Aged Nausea - epidemiology Oligopeptides - administration & dosage Oligopeptides - adverse effects Oligopeptides - therapeutic use OPTIMIZE Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Protease Inhibitor Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Ribavirin - adverse effects Ribavirin - therapeutic use RNA, Viral - blood Treatment Outcome |
| title | Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T21%3A49%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telaprevir%20Twice%20Daily%20Is%20Noninferior%20to%20Telaprevir%20Every%208%20Hours%20for%20Patients%20With%20Chronic%20Hepatitis%20C&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Buti,%20Maria&rft.date=2014-03-01&rft.volume=146&rft.issue=3&rft.spage=744&rft.epage=753.e3&rft.pages=744-753.e3&rft.issn=0016-5085&rft.eissn=1528-0012&rft_id=info:doi/10.1053/j.gastro.2013.11.047&rft_dat=%3Cproquest_cross%3E1501834350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1501834350&rft_id=info:pmid/24316262&rft_els_id=1_s2_0_S0016508513017289&rfr_iscdi=true |